Your browser doesn't support javascript.
loading
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley, David M; Oaknin, Ana; Monk, Bradley J; Selle, Frédéric; Rojas, Carlos; Gladieff, Laurence; Berton, Dominique; Leary, Alexandra; Moore, Kathleen N; Estevez-Diz, Maria D P; Hardy-Bessard, Anne-Claire; Alexandre, Jérôme; Opperman, Christina P; de Azevedo, Carla Rameri A S; Randall, Leslie M; Feliu, Waldo Ortuzar; Ancukiewicz, Marek; Ray-Coquard, Isabelle.
Affiliation
  • O'Malley DM; The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. Electronic address: David.O'Malley@osumc.edu.
  • Oaknin A; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: aoaknin@vhio.net.
  • Monk BJ; Arizona Oncology (US Oncology Network), Creighton University School of Medicine, Phoenix, AZ, United States. Electronic address: Bradley.Monk@usoncology.com.
  • Selle F; Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France. Electronic address: fselle@hopital-dcss.org.
  • Rojas C; Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile. Electronic address: cirojas@bradfordhill.cl.
  • Gladieff L; Institut Claudius Regaud-Institut Universitaire du Cancer (IUCT)-Oncopole, Toulouse, France. Electronic address: gladieff.laurence@iuct-oncopole.fr.
  • Berton D; ICO Centre René Gauducheau, Saint-Herblain, France. Electronic address: dominique.berton@ico.unicancer.fr.
  • Leary A; Gustave Roussy Cancer Center, Villejuif, France. Electronic address: alexandra.leary@gustaveroussy.fr.
  • Moore KN; Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: Kathleen-Moore@ouhsc.edu.
  • Estevez-Diz MDP; Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.
  • Hardy-Bessard AC; Clinique Armoricaine de Radiologie, Saint-Brieuc, France. Electronic address: ac.hardy@cario-sante.fr.
  • Alexandre J; Hôpital Cochin, Paris, France. Electronic address: jerome.alexandre@cch.aphp.fr.
  • Opperman CP; Hospital Mãe de Deus, Porto Alegre, Brazil.
  • de Azevedo CRAS; Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Recife, Brazil.
  • Randall LM; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: leslie.randall@vcuhealth.org.
  • Feliu WO; Agenus Inc., Lexington, MA, United States. Electronic address: waldo.ortuzar@agenusbio.com.
  • Ancukiewicz M; Agenus Inc., Lexington, MA, United States. Electronic address: marek.ancukiewicz@agenusbio.com.
  • Ray-Coquard I; Centre Léon Bérard, Lyon, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr.
Gynecol Oncol ; 163(2): 274-280, 2021 11.
Article in En | MEDLINE | ID: mdl-34452745
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Neoplasm Recurrence, Local Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2021 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Neoplasm Recurrence, Local Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2021 Document type: Article Country of publication: Estados Unidos